Company profile: Micreos
1.1 - Company Overview
Company description
- Provider of phage-based precision antimicrobials and engineered endolysins targeting pathogenic bacteria without harming the beneficial microbiome. Offerings include antimicrobial vectors; MEndoB for staphylococcal infections, including MRSA, for systemic/topical use; XZ.700 for S. aureus colonization in lesional skin (CTCL); and clinical/pre-clinical molecules for out-licensing, with focus areas including CTCL and AD.
Products and services
- MEndoB: Precision-engineered antimicrobial targeting staphylococcal infections, including resistant strains like MRSA, suitable for systemic and topical use
- XZ.700: Recombinant endolysin engineered to control Staphylococcus aureus colonization in lesional skin, demonstrating promise in treating Cutaneous T-cell Lymphoma
- Antimicrobial Vectors: Phage-derived genetic scaffolds architected to create precision antimicrobials that treat bacterial infections without damaging the beneficial microbiome
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Micreos
Excelimmune
HQ: United States
Website
- Description: Provider of fully human recombinant polyclonal antibodies for therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Excelimmune company profile →
Genelabs Technologies
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D focused on discovering and developing therapies for infectious diseases, offering drug discovery services and medications including Morphine for severe pain, Atomoxetine (Strattera) for ADHD, Finasteride (Propecia) for male pattern hair loss, and Valacyclovir (Valtrex) for herpes and shingles.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genelabs Technologies company profile →
Pharmasset
HQ: United States
Website
- Description: Provider of novel oral therapeutics to treat viral infections, with a primary focus on hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV). Clinical-stage pharmaceutical company committed to discovering, developing, and commercializing antiviral drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharmasset company profile →
Rational Vaccines
HQ: United States
Website
- Description: Provider of pre-clinical live-attenuated herpes simplex virus vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rational Vaccines company profile →
Topica Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical research-stage topical treatments targeting fungal infections of the nail.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Topica Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Micreos
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Micreos
2.2 - Growth funds investing in similar companies to Micreos
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Micreos
4.2 - Public trading comparable groups for Micreos
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →